← Back to All Filings

Viatris Director Acquires 24,835 Shares via RSU Vesting

Low SignificanceMarch 10, 2026 at 7:18:01 PM EDT

Viatris Inc

$VTRS4CIK: 0001792044

Subscribe to track VTRS

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Viatris Director Acquires 24,835 Shares via RSU Vesting

Company: Viatris Inc (VTRS) Form: 4 | Filed: 2026-03-10 Significance: Low

Insider: FINNEY ELISHA W Relationship: Director

Transaction: • Type: RSU Vesting & Grant • Shares Acquired: 24,835 • Price: $0.00 • Value: $0 (Compensation) • Owned After: 62,667

Key Insight: Routine director compensation event involving the vesting of previous Restricted Stock Units and the grant of new units. No open market activity.

Market Context: Transaction represents negligible dilution (0.002% of outstanding shares) for this $17.19B market cap company.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: Viatris Inc (VTRS)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Routine director compensation involving RSU vesting and new annual grants; no open market activity.
  • Market Impact: Neutral - standard corporate governance procedure.

Company Information

FieldValue
CompanyViatris Inc
Ticker SymbolVTRS
CIK0001792044
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameFINNEY ELISHA W
CIK0001217439
Title/PositionN/A (Director)
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2026-03-06
Transaction CodeM (Exercise/Vesting) & A (Grant)
Security TypeCommon Stock & RSUs
Shares Acquired24,835 (Vested)
Price Per Share$0.00
Total Value$0.00 (Compensation)
Shares Owned After62,667
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$0 (Non-monetary)
% of Market Cap0.00%
Shares Transacted24,835
% of Shares Outstanding0.002%
Post-Transaction Ownership62,667 shares (0.005% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: With a market cap of $17.19 billion, this compensation event is financially immaterial.
  • Ownership Concentration: The insider holds a very small fraction (0.005%) of the 1.15 billion shares outstanding.
  • Dilution Impact: The vesting of 24,835 shares and new grant of 15,890 RSUs represents negligible dilution to existing shareholders.
  • Transaction Significance: This is a scheduled vesting event and annual grant, not an investment decision based on current market valuation.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is purely administrative (vesting of equity awards) and does not reflect insider sentiment regarding the stock's future performance.

Volume & Sentiment

  • Expected Volume Impact: None.
  • Sentiment Indicator: Neutral.

Additional Context

Transaction Notes

  • Details: The reporting person acquired 23,660 shares from RSU vesting and 1,175 shares from Dividend Equivalent Units. Additionally, they received a new grant of 15,890 RSUs vesting in 2027.
  • Timing: Occurred on March 6, 2026, likely aligning with the company's annual equity award cycle.
Topics:#VTRS#Viatris#Form4#InsiderTrading#StockMarket#Pharma#CorporateGovernance#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.